MarketsTop Movers

Constellation rose 12% on Google's nuclear deal, and genomics funds sank

Constellation Energy rose 12% on Tuesday, October 6, after Google agreed to fund 890 megawatts of reactor upgrades, and ARK's genomics fund fell 8.8%.

Oct 6, 2026 · 2 min read · ETF.net Research

An aerial view of a nuclear power plant's cooling tower and reactor building surrounded by a field of solar panels.

Key takeaways

Google is paying to squeeze more power from existing reactors.
Three nuclear operators drove most of an active utility fund's gain.
Two genomics stocks hit 52-week highs, then fell double digits.
Moderna's huge year couldn't stop it sliding on Tuesday.

Constellation Energy rose 12% on Tuesday after Google agreed to fund upgrades that would get more electricity from reactors the company already runs.

The 20-year contract covers 890 megawatts of new capacity at 11 reactors in Illinois, Pennsylvania and New Jersey. The first of that power is expected in 2028, and Constellation said it would invest more than $4.3 billion. Google and Constellation said 890 megawatts is as much electricity as a large new reactor.

Google also signed a 15-year contract for 2,700 megawatts from Constellation plants that are already producing. That is power on the grid today, not more new capacity.

Talen Energy rose 12%, and Vistra rose 11%. Constellation, Talen and Vistra, the three largest holdings in Virtus's actively managed utility fund, UTES, are about a third of it, and they accounted for most of its 5.6% gain. The large U.S. utility companies, held in XLU, gained 3%.

Three nuclear operators were UTES's largest holdings, and its biggest gainers

Top 10 holdings weights as of October 6, 2026; Tuesday price returns

The other seven top holdings rose 0.7% to 2.8%.

VanEck's fund of uranium miners and nuclear utilities, NLR, gained 5.5%. Constellation, its largest holding, contributed the most to that gain. Cameco, a uranium miner in the fund, rose 6.3%.

The S&P 500 and the Nasdaq Composite closed at records, and the fund holding the S&P 500, SPY, rose 0.55%.

Genomics stocks reversed

Twist Bioscience fell 19% and 10x Genomics fell 17%. Both hit a 52-week high earlier in the session. Tempus AI fell 14%.

Reports on Tuesday tied Twist's early drop to sales by company insiders, including chief executive Emily Leproust.

ARK's genomics fund, ARKG, fell 8.8%. Twist, 10x Genomics and Tempus, three of its largest holdings, accounted for more than half the loss.

UTES gained 5.6%; ARKG lost 8.8%

Tuesday, October 6, 2026 fund returns

UTES+5.6%
NLR+5.5%
XLU+3.0%
SPY+0.5%
ARKG−8.8%

XLU gained 3%; SPY, the S&P 500 fund, barely moved.

A fund of U.S. biotech stocks, XBI, fell 3.4%. Moderna, one of its largest holdings, is up 536% this year. It hit a 52-week high on Tuesday and finished the day down 7.8%.

ETFs in this story

BUTESVirtus Reaves Utilities ETF60/100 DARKGARK Genomic Revolution ETF36/100 ANLRVanEck Uranium and Nuclear ETF74/100 AXLUState Street Utilities Select Sector SPDR ETF76/100 AXBIState Street SPDR S&P Biotech ETF82/100

Frequently asked questions

What did Google agree to with Constellation Energy?

Google signed a 20-year contract to fund 890 megawatts of new capacity at 11 existing Constellation reactors, with first power expected in 2028, plus a separate 15-year contract for 2,700 megawatts from plants already producing.

Why did UTES rise more than XLU?

Constellation, Talen and Vistra, which each rose 11% to 12%, make up about a third of UTES and accounted for most of its 5.6% gain, while XLU gained 3%.

Why did ARKG fall 8.8%?

Twist Bioscience, 10x Genomics and Tempus AI, three of its largest holdings, fell 14% to 19% and accounted for more than half the loss.

What was tied to Twist Bioscience's drop?

Reports on Tuesday tied Twist's early drop to sales by company insiders, including chief executive Emily Leproust.